LBRX — LB Pharmaceuticals Inc Common Stock stock price, charts and financials

QT90LB Pharmaceuticals Inc Common Stock

LB Pharmaceuticals Inc Common Stock (NASDAQ: LBRX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
42.47
+0.33+0.78%
OverviewShort InterestFilings
LBRXQT90LB Pharmaceuticals Inc Common Stock·NASDAQ
42.47+0.78%
News
Up 0.8% — LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunity (seekingalpha.com).
Medium confidence
TA
Loading chart...
Screen all →
NKTR-1.84%$67.10RAPP-3.58%$40.45GHRS-1.60%$28.26ZYME-3.31%$26.57MESO+1.75%$15.13AGIO-1.61%$33.07ZBIO-1.47%$31.50RXRX+8.19%$3.83
Snapshot
Index-P/E-EPS (ttm)-Insider Own-Shs Outstand28.68MPerf Week-4.84%
Market Cap1.22BForward P/E-EPS next Y-5.04Insider Trans-Shs Float20.76MPerf Month-13.22%
Enterprise Value893.90MPEG-EPS next Q-1.63Inst Own-Short Float25.42%Perf Quarter41.57%
Income-25.00MP/S0.00EPS this Y-Inst Trans-Short Ratio16.00Perf Half Y77.03%
Sales0.00P/B3.67EPS next Y10.20%ROA-23.69%Short Interest5.28MPerf YTD90.79%
Book/sh11.58P/C3.71EPS next 5Y-ROE-25.91%52W High50.16 -15.33%Perf Year160.39%
Cash/sh11.44P/FCF-EPS past 3/5Y-ROIC-28.07%52W Low13.36 217.89%Perf 3Y-
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility3.74% 4.24%Perf 5Y-
Dividend TTM-EV/Sales0.00EPS Y/Y TTM80.71%Oper. Margin0.00%ATR (14)2.19Perf 10Y-
Dividend Ex-Date-Quick Ratio15.08Sales Y/Y TTM-Profit Margin0.00%RSI (14)40.52Recom2.00
Dividend Gr. 3/5Y-Current Ratio15.08EPS Q/Q-18.75%SMA20-8.87%Beta0.54Target Price51.86
Payout0.00%Debt/Eq0.01Sales Q/Q-SMA50-0.34%Rel Volume1.54Prev Close42.14
Employees49LT Debt/Eq0.01EarningsNov 05SMA20041.71%Avg Volume344.35KPrice42.47
IPO DateSep 11, 2025Option/ShortYes / YesEPS/Sales Surpr.-112.78% -Net Debt/EBITDA3.17Volume531,640Change0.78%
Analyst Ratings
DateActionAnalystRatingTarget
Aug-24-26ReiteratedHC Wainwright & Co.Buy$45 → $60
Aug-13-26ReiteratedStifel Nicolaus$40 → $53
Aug-12-26ReiteratedBMO CapitalOutperform$46 → $54
Aug-03-26ReiteratedPiper Sandler$78
Jul-20-26InitiatedBMO CapitalOutperform$46
Jul-07-26InitiatedWolfe ResearchOutperform$45
May-17-26ReiteratedRoth Capital$31 → $37
Apr-27-26InitiatedH.CBuy$45
Apr-10-26InitiatedCraig-Hallum$36
Mar-27-26ReiteratedStifel Nicolaus$35 → $40
Latest News· Times ET
Sep-18-26
Sep-18-2612:25AM
LB Pharmaceuticals: One Methyl Group, Two Enantiomers, And A Bullish $5 Billion Opportunityseekingalpha.com
Sep-15-26
Sep-15-2608:00AM
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D. as Chief Medical OfficerYahoo
04:00AM
LB Pharmaceuticals Appoints Susan G. Kozauer, M.D.globenewswire.com
Sep-09-26
Sep-09-2604:00AM
IPO Stock LB Pharma Has Tripled In Under A Year. Is It A Takeover Target?investors.com
Sep-03-26
Sep-03-2612:05PM
LB Pharmaceuticals to Participate in Upcoming September Investor Eventsglobenewswire.com
04:07AM
LB Pharmaceuticals Appoints Joseph Miller CFOBenzinga
04:00AM
LB Pharmaceuticals Appoints Joseph Miller as Chief Financial Officerglobenewswire.com
Aug-24-26
Aug-24-2605:30AM
Analog Devices To Rally Around 81%? Here Are 10 Top Analyst Forecasts For MondayBenzinga
Aug-16-26
Aug-16-2606:54PM
Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say YesSeekingAlpha
Aug-11-26
Aug-11-2604:05AM
LB Pharmaceuticals Q2 EPS $(1.71) Misses $(0.80) EstimateBenzinga
04:00AM
LB Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Updateglobenewswire.com
Aug-03-26
Aug-03-2602:33AM
HC Wainwright & Co. Reiterates Buy on LB Pharmaceuticals, Maintains $45 Price TargetBenzinga
Jul-29-26
Jul-29-2604:02AM
LB Pharmaceuticals Commences ~$150M Offering Of Common Shares, Pre-Funded WarrantsBenzinga
04:00AM
LB Pharmaceuticals Announces $150 Million Private Placementglobenewswire.com
Jul-22-26
Jul-22-2604:00AM
LB Pharmaceuticals Announces Accelerated Timing of Topline Results from the Phase 3 NOVA-2 Trial of LB-102 in Schizophreniaglobenewswire.com
Company

This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
000—
Cost of Goods Sold Incl. D&A
000—
Gross Profit
000—
Selling, General and Administrative Excl. Other14144—
Research and Development17518—
Other Operating Expense-10-1—
Operating Income-30-65-11—
Interest Expense005—
Unusual Expense
————
Non-Operating Income (Expense)5210—
Net Income Before Taxes-25-63-6—
Income Taxes
000—
Consolidated Net Income-25-63-6—
Net Income From Continuing Operations-25-63-6—
Net Income-25-63-6—
EPS (Recurring)-1.00-17.83-1.77—
EPS (Basic, Before Extraordinaries)-1.00-17.83-1.77—
EPS (Diluted)-1.00-17.83-1.77—
EBITDA-25-63-1—
Other After Tax Adjustments
————
Stock Option Compensation Expense
————
Price To Earnings Ratio
————
Price To Sales Ratio
————
Gross Margin
————
Operating Margin
————
Net Margin
————
Shares Outstanding2544—
Market Capitalization557———
Operating Lease Expense
————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.